Arthneeti

Gland Pharma Q1 FY27 Share Price & Earnings Call Analysis

₹3,095.90+0.70% today
Market cap
₹51,092 Cr
P/E
44.61
ROE
10.68%
PEG
5.37
Price to sales
7.59
Debt to equity
0.03
52W high / low
₹3,151 / ₹1,597
Sales growth (5Y)
13.18%
EBITDA margin
26.04%
Net profit margin
16.20%
Promoter holding
45.75%
Sales (last year)
₹6,725 Cr

Established in Hyderabad, India in 1978, Gland Pharma has grown over the years from a contract manufacturer of small volume liquid parenteral products, to become one of the largest and fastest growing injectable-focused companies, with a global footprint across 60 countries, including the United States, Europe, Canada, Australia, India and other markets. We operate primarily under a business to business (B2B) model and have an excellent track record in the development, manufacturing and marketing of complex injectables. This presence across the value chain has helped us witness exponential growth. We are promoted by Shanghai Fosun Pharma, a global pharmaceutical major.

Guidance scorecard · Q1 FY27 call

What Gland Pharma Ltd's management guided
and where it ranks in Pharmaceuticals & Biotechnology

#6of 84 in
Pharmaceuticals & Biotechnology
Revenue20–40%MarginsUp 2%+CapexPlannedFundraisingPlannedOrder bookWhat management said

RevenueQ1 FY27 call

20–40%
  • Gland Pharma targets a 15% CAGR over the next 4-5 years; new contracts could push growth closer to 20% annually.
  • U.S. revenues currently about USD 110-120 million, expected to grow faster than the market (3-4%) due to new product launches and operational efficiencies.
  • Complex product portfolio contribution is expected to increase post FY29, potentially taking a larger share of U.S. business revenue.
  • CDMO business aims to comprise around 30% of consolidated revenues in the near term, with higher margins than traditional IP-led business.
  • Bag line and ophthalmic products capacity expansions pending FDA approvals may accelerate growth beyond 15% in the current fiscal year.

2 more points from Gland Pharma Ltd's call on revenue

Create a free account to keep reading this call

Full Q1 FY27 analysis

MarginsQ1 FY27 call

Up 2%+

See what Gland Pharma Ltd said on margins — free account, 30 seconds.

Full Q1 FY27 analysis

CapexQ1 FY27 call

Planned
  • Ongoing execution of a recently announced INR 2,000 crores capital expenditure program.
  • Q1 FY27 capex of INR 1,132 million towards capacity expansion, capability enhancements, infrastructure additions supporting CDMO and fill/finish platforms.
  • Immediate INR 165 crores capex for installing an isolator line in oncology plant (to be installed by January).
  • Capex towards vial, ophthalmic, BFS lines, and liposome products at India sites on track.
  • Capacity expansion projects approved and prioritized to meet growing CDMO collaboration demand.
  • Growth capex at Cenexi for adding a new block underway.
  • Neuland collaboration: capex for building an API block has started.

2 more points from Gland Pharma Ltd's call on capex

Create a free account to keep reading this call

Full Q1 FY27 analysis

FundraisingQ1 FY27 call

Planned

See what Gland Pharma Ltd said on fundraising — free account, 30 seconds.

Full Q1 FY27 analysis

Order bookQ1 FY27 call

  • Current order book size mentioned is around INR600 crore to INR700 crore, expected to increase further.
  • New contracts recently signed will contribute about 12% to current revenue, supporting a 20% growth over the next 4 years.
  • The company is actively working on both brownfield and greenfield expansions to support volume growth.
  • There is ongoing negotiation/discussion with partners for additional contracts, expected to provide more clarity on growth and order book by next quarter.
  • CDMO business currently contributes about 50% of revenue, with a near-term target to reach 30% on a consolidated basis.

2 more points from Gland Pharma Ltd's call on the order book

Create a free account to keep reading this call

Full Q1 FY27 analysis
Full Pharmaceuticals & Biotechnology ranking

Ranges are what management guided for revenue growth and margins on the latest earnings call. Not investment advice, and not a forecast of returns.

Potential multibaggers · Q2 FY27

Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance

  1. Strong growth
    2
  2. Strong growth
    1
  3. Strong growth
    3
See all potential multibaggersWhere does Gland Pharma Ltd rank?

Portfolio builder

Build your portfolio
from the top-ranked stocks

  1. 1. Pick 3–15 stocks
  2. 2. Choose large, mid or small cap and your sectors
  3. 3. Get a portfolio built from the rankings
Build my portfolio

Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.

Peers

Pharmaceuticals & Biotechnology companies ranked on guidance

#CompanyRevenue guidedMargin guidedMarket capP/E
140%+Up 2%+₹556 Cr22.1
240%+Up 0–2%₹215 Cr22.2
340%+Flat₹16,144 Cr—
440%+Flat₹6,072 Cr48.0
540%+Flat₹40 Cr—
6Gland Pharma LtdThis stock20–40%Up 2%+₹50,220 Cr43.8

Sign up free to see every company in the sector ranking and track Gland Pharma Ltd.

Pro shows every company guiding 40%+ revenue growth →Full Pharmaceuticals & Biotechnology ranking

Financials of Gland Pharma Ltd

Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.

Financials of Gland Pharma Ltd

Quarterly Results

Quarter-by-quarter operating performance

Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Sales +7851,2091,3731,5451,5371,4021,4061,3841,4251,5061,4871,6951,743
Expenses +6179151,0491,1891,1791,1371,1091,0241,0771,1381,1731,2601,230
Operating Profit168294324356359264297360348368314435513
OPM %21%24%24%23%23%19%21%26%24%24%21%26%29%
Other Income +-183853374251605844588439111
Interest25651066237128410
Depreciation3865811059392949696101106108109
Profit before tax111261290283298218257299288313284362506
Tax %29%26%33%32%35%34%36%32%35%31%35%28%28%
Net Profit +79194194192192144164205187215184261367
EPS in Rs4.7811.7911.7811.6511.688.739.9312.4211.3213.0811.1515.8722.26

Financials of Gland Pharma Ltd

Profit & Loss

Annual income statement trend

Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Sales +2,6333,4634,4013,6255,6655,6166,431
Expenses +1,6782,1612,8902,6004,3324,3484,801
Operating Profit9551,3021,5101,0251,3331,2691,630
OPM %36%38%34%28%24%23%25%
Other Income +139135224184170214292
Interest7357264233
Depreciation9599110147345378424
Profit before tax9931,3351,6191,0551,1331,0631,465
Tax %22%25%25%26%32%34%30%
Net Profit +7739971,2127817726991,027
EPS in Rs49.8860.9473.7547.4246.9042.4062.35
Dividend Payout %0%0%0%0%43%42%32%

Financials of Gland Pharma Ltd

Balance Sheet

Capital structure and asset base

Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital16161616161616
Reserves3,6315,8877,1417,9428,7079,13410,341
Borrowings +5454372314284
Other Liabilities +4355896718141,5151,7081,869
Total Liabilities4,0866,4967,8348,77810,61111,17312,511
Fixed Assets +9689541,5021,5713,9474,1474,492
CWIP188338191177238151342
Investments001550000
Other Assets +2,9295,2045,9867,0306,4266,8757,676
Total Assets4,0866,4967,8348,77810,61111,17312,511

Financials of Gland Pharma Ltd

Cash Flows

Operating, investing and financing cash movement

Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity +7016057913649979151,031
Cash from Investing Activity +-761-1,520-9991,211-1,7491,718138
Cash from Financing Activity +-71,2383515-799-433-417
Net Cash Flow-67323-1741,590-1,5522,199752
Free Cash Flow530377269141599521538
CFO/OP99%70%79%66%98%100%91%

Financials of Gland Pharma Ltd

Ratios

Working capital efficiency and return ratios

Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days8371898810099107
Inventory Days250312205421278294284
Days Payable829880127129143136
Cash Conversion Cycle251285214382250250255
Working Capital Days161169168242155173145
ROCE %28%25%15%14%12%15%

Guidance history

How Gland Pharma Ltd's guidance has moved, call by call

CallRevenueMarginsCapexFundraisingOrder book
Q1 FY27 call →20–40%Up 2%+PlannedPlanned—
Q4 FY26 call →10–20%FlatPlanned—Rising
Q3 FY26 call →10–20%FlatPlanned—Rising
Q2 FY26 call →10–20%FlatPlanned——

What management guided on each call, newest first. Not investment advice, and not a forecast of returns.

46out of 100

Momentum score · price trend

46 out of 100 — Steady

Over the past year its share price has moved roughly in the middle of the stocks we track.

PeriodShare price changeBetter than … of 1,910 stocks
Last 12 months+62.4%89%
Last 6 months+76.8%94%
Last 3 months+23.7%90%

The price is 27.8% below its all-time high of ₹4,287.2 (13 Aug 2021). Stocks more than 20% below their peak have their score halved, so 91 became 46.

How we calculate it

“Better than 30%” means that over that period the share price did better than 30 out of every 100 stocks we track (1,910 Indian companies worth ₹500 Cr or more, with at least a year of prices).

The score weighs the longer periods more: 40% × 12-month + 40% × 6-month + 20% × 3-month. For Gland Pharma Ltd: 0.4 × 89 + 0.4 × 94 + 0.2 × 90 = 91, halved to 46 because the price is more than 20% below its all-time high.

Strengthening is 70 and above, Steady 40 to 70, Cooling below 40. Scores are recalculated every night after the market closes.

Full methodology →

This describes only how the share price has moved up to 30 Oct 2026, compared with other stocks. It says nothing about the business, and it is not a prediction, a price target or a recommendation to buy or sell.

Continue your research

What Gland Pharma Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

  • Sigachi Industries Ltd (Q2 FY27)

    Year-on-Year (YoY) Revenue Growth: 18.09% (Q2 FY27 vs Q2 FY26) . Key investor presentation takeaways from Sigachi Industries Ltd's Q2 FY27 investor presentation

  • Advanced Enzyme Technologies Ltd (Q2 FY27)

    Q2 FY27 revenue from operations: ₹2,145 million, up 16% YoY from ₹1,845 million in Q2 FY26 (Page 13, 5). Key investor presentation takeaways from Advanced Enzym

  • IOL Chemicals (Q2 FY27)

    Q2 FY27 revenue from operations: ₹795.0 Cr, a 40.1% year-on-year (YoY) increase from ₹567.5 Cr in Q2 FY26 (Page 7). Key investor presentation takeaways from IOL

  • Lyka Labs Ltd (Q2 FY27)

    Year-on-Year revenue growth for the quarter: approximately 104.5% increase (8,650.89 vs 4,230.94 lakhs). Key results statement takeaways from Lyka Labs Ltd's Q2

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Torrent Pharmaceuticals Ltd